5 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group

Page 5 of 5

1. ImmunoGen, Inc. (NASDAQ:IMGN)

Redmile Group Stake Value: $46,825,000
Percentage of Redmile Group’s 13F Portfolio: 0.81%
Number of Hedge Fund Holders: 26
Price per Share as of Nov. 23, 2021: $5.06

ImmunoGen, Inc. (NASDAQ:IMGN) is dedicated to researching and developing antibody-drug conjugates to enhance cancer patient outcomes. Peter Kolchinsky’s RA Capital Management owns 18.42 million shares of ImmunoGen, Inc., worth over $104.43 million, topping the list of over 867 hedge funds tracked by Insider Monkey.

With a $46.83 million stake in ImmunoGen, Jeremy Green’s Redmile Group owns 8.26 million shares of the company in the third quarter of 2021. In addition, our database shows that 26 hedge funds held stakes in the company in the third quarter.

You can also take a peek at 10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman and 10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson.

Page 5 of 5